CYP21 gene mutations in Brazilian patients with 21-hydroxylase deficiency from the Amazon region

HUMAN AND MEDICAL GENETICS

RESEARCH ARTICLE

CYP21 gene mutations in Brazilian patients with 21-hydroxylase deficiency from the Amazon region

Tarcísio André Amorim de Carvalho^I; Izabel Cristina Neves de Souza^I; France Keiko Nascimento Yoshioka^I; Milena Coelho Fernandes Caldato^II; Nilza Nei Torres^II; Lena Stilianidi Garcia^III; João Farias Guerreiro^I

^ILaboratório de Genética Humana e Médica, Departamento de Patologia, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil

^IIHospital Universitário João de Barros Barreto, Departamento de Endocrinologia, Universidade Federal University do Pará, Belém, PA, Brazil

^IIIFundação Santa Casa de Misericórdia, Belém, PA, Brazil

^{Send correspondence to}

ABSTRACT

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (P450c21, CYP21) accounts for about 95% of all CAH cases. The incidence of CYP21 gene mutations has been extensively studied in the last years, but in Brazil it has been investigated only in Southeast Brazilian patients. This study is the first report on the distribution of CYP21 mutations in patients from the Amazon region. Direct sequencing of the CYP21 gene identified at least one mutation in 96% of the studied chromosomes. The most common mutations found were IVS2-13A/C > G (36%), Q318X (12%), V281L (12%), 1760_1761insT (9%), Cluster E6 (7%), and P30L (7%). The worldwide most common mutations were identified among patients from the Amazon region at frequencies that may be expected for a population resulting from the admixture of Europeans (predominantly Portuguese), African Blacks and Amerindians, in proportions that differ from those estimated for South Brazilian populations. Interethnic mixture may explain the differences in the frequencies of some mutations between Brazilian patients from the Amazon and from the Southeast of the country. However, the differences found may also be due to variation in the number of patients with the different clinical forms of 21-hydroxylase deficiency in the studies carried out so far.

Key words: Amazon region, 21-hydroxylase deficiency, DNA sequencing.

Introduction

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OH, P450c21, CYP21) is a disorder of the adrenal cortex characterized by cortisol deficiency, with or without aldosterone deficiency, and excess of androgen. It accounts for about 95% of all CAH cases.

Reduced levels of cortisol promote an overproduction of adrenocorticotrophic hormone (ACTH) and the consequent increase in the secretion of androgen, resulting in clinical manifestations that include a severe type (classical form) and a milder type (nonclassical form, NC), whose carriers remain either asymptomatic or develop symptoms during childhood or at puberty. The classical form is subdivided into the simple virilizing (SV) form, with prenatal virilization of the external genitalia in the female fetus, and the salt-wasting (SW) form that consists in the virilization of the female fetus and can lead to a salt-wasting crisis in both genders (New et al., 1989; Morel and Miller, 1991). The classical form occurs at a rate between 1:5,000 and 1:15,000 among live North American and European neonates, while the nonclassical form occurs in approximately 0.2% of the general white population. This rate is especially high in Ashkenazi Jews and a part of the Mediterranean population (i.e., Italians, Hispanics) (Trakakis et al., 2005).

The gene encoding human 21-OH (CYP21) is located at 6p21.3, within HLA class III, approximately 30 kb apart from its pseudogene (CYP21P), which is inactive due to the presence of several inactivating mutations (White et al., 1985; Higashi et al., 1986; Lee, 2001). CYP21 and CYP21P, both with 10 exons, share about 98% homology in their exons and about 96% in their introns. These genes are included in the RCCX module, composed of four tandem genes: RP1-C4A-CYP21P-TNXA-RP2-C4B-CYP21-TNXB (Lee et al., 2004). Because of the high homology and tandem-repeat organization, this gene cluster is subject to a high frequency of recombination events, which can lead to two distinct situations: (i) unequal crossing-over during meiosis, which can produce a wide variety of rearrangements depending on the breakpoints, such as gene duplications and gross gene deletions encompassing C4 and CYP21; (ii) large and short gene conversion events that transfer deleterious mutations present in the CYP21P gene to CYP21 (Higashi et al., 1988; Tusie-Luna and White, 1995; White et al., 1986). About 95% of the mutant alleles are generated by the conversion of DNA sequences from the CYP21P pseudogene to the active CYP21 gene, while the remainder are new mutations not found in the pseudogene (White and Speiser, 2000).

To date, according to the Human Gene Mutation Database (HGMD-2007), 103 mutations of the CYP21 gene have been reported, most of them nonsense/missense (64), splicing (7), regulatory (1), small deletions (11), small insertions (8), small indels (3), gross deletions (4), gross insertions (2), and complex rearrangements (3). However, apart from gene deletions and large gene conversions, nine mutations are reported with a higher frequency, namely P30L, IVS2-13A/C > G, 707_714del8 (exon 3), I172N, V281L, 1760_1761insT, Q318X, R356W, and P453S (Morel and Miller, 1991).

Most patients are compound heterozygotes (i.e., they have different mutations on the two chromosomes), and the clinical phenotype is generally related to the less severely mutated allele and, consequently, to the residual 21-OH activity (Speiser et al., 1992; Wilson et al., 1995; Jaaskelainen et al., 1997; Krone et al., 2000).

The distribution of CYP21 gene mutations in patients of Southeast Brazil has been investigated previously, and the results obtained reveal that the mutation frequencies did not differ from those found worldwide, but at least 13 new mutations were identified (Bachega et al., 1998; Paulino et al., 1999; Witchel et al., 2000; Torres et al., 2003). However, there are no genetic reports of studies conducted on patients of other areas, especially of the North of the country, where the population results from intense miscegenation of Europeans, Africans and Amerindians.

This is the first report on the prevalence of point mutations and short insertions/deletions in the CYP21 gene of patients with 21-OH deficiency from the State of Pará, in the Brazilian Amazon region.

Materials and Methods

Subjects and DNA sample preparation

CYP21 gene analysis was performed in 46 unrelated patients with clinical symptoms of 21-OH deficiency, seen at Foundation Santa Casa de Misericórdia do Pará and University Hospitals Bettina Ferro de Souza and João de Barros Barreto. The patients were referred to the Human and Medical Genetics Laboratory for karyotyping and investigation of gene CYP21 mutations. Either the patients or their legal guardians signed an informed consent for the participation in the research. The patients' age varied from 15 days to 84 years, and 61% of them were classified as genetic females. Thirty-four patients presented the classical form of the disease (19 simple virilization and 15 salt-wasting cases), and 12 had the non-classical form. The clinical diagnosis of the form of the disease (SV, SW or NC) was made by pediatric endocrinologists and gynecologists at the different hospitals from where the patients were referred. SW CAH was characterized by the onset of hyperkalemia, hyponatremia, dehydration, and/or shock in the first month of life. Female patients had ambiguous genitalia. The SV form of 21-OH deficiency was diagnosed based on the presence of ambiguous genitalia along with no evidence of sodium depletion. The NC form was characterized by late-onset signs of androgen excess, including growth acceleration and advancement of bone age in children, or menstrual disturbances, infertility and hirsutism in adult women. None of the patients had consanguineous parents.

Peripheral blood was collected and the leukocytes were used for DNA extraction, following the phenol/chloroform DNA extraction protocol of Sambrook et al. (1989).

Selective amplification of the CYP21 gene

Selective PCR amplification of the CYP21 gene was performed in two segments, using primers P1 (5'-TCGG TGGGAGGGTACCTGAAGGT-3') and P2 (5'-GCATCT CCACGATGTGAT-3'), and P3 (5'-CCGGACCTGTCCT TGGGAGACTACT-3') and P4 (5'-CTGAGCGGCTGGG TGAAATGGAAC-3'), respectively. Fragment 1 represents a 1339-bp segment extending from exon 1 to exon 6. Fragment 2 is a 2220-pb fragment extending from the 8-bp deletion in exon 3 to beyond exon 10, according to Oriola et al. (1997). These two overlapping segments amplify the whole coding region of the CYP21 gene using the Elongase kit (Invitrogen). The 5'UTR and the 3'UTR region were not included in this study.

DNA sequencing

Each CYP21 exon and its flanking sequences were amplified by nested-PCR using the P1-P2 and P3-P4 reaction products (diluted 1:100) as templates, and internal primers designed according to gene sequence. Primer sequences are available upon request. After purification with an EXOSAP kit (USB), the PCR products were directly sequenced with the forward and reverse primers used for nested-PCR, using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems). The reaction products were electrophoresed in an automated ABI Prism 3130 sequencer (Applied Biosystems).

Results

Mutations were identified in 45 of the 46 patients, corresponding to a spectrum of 22 different mutations: 17 missense or nonsense mutations, two short insertions, two short deletions and one splicing mutation. The frequencies of the different mutations found are shown in Table 1. The most common mutations found were IVS2-13A/C > G (35%), Q318X (12%), and V281L (12%). Mutations 1760_1761insT, Cluster E6, and P30L showed somewhat lower frequencies: 9.0%, 7.0%, and 7.0%, respectively. These six mutations account for 82% of all mutations found.

Regarding the distribution of the mutations by clinical forms of the disease, IVS2-13A/C > G was the most frequent among patients with the classical forms, accounting for 51% of the mutations found in the salt-wasting form and 30% in the simple virilizing form, while in patients with the nonclassical form, mutations Q318X and V281L were the most common (25% and 20%, respectively), followed by mutation IVS2-13A/C > G (15%).

Six patients (13%) were homozygous for a single mutation, 13 (28%) were homozygous for one mutation and heterozygous for one or more additional mutations, 14 (30%) were compound heterozygotes with different mutations on each chromosome, 12 (26%) patients were simple heterozygotes, and one patient (2%) had no mutation at all.

The presence of at least one polymorphism was detected in six of the 11 heterozygous patients, and more than one polymorphism was identified in one of two patients who did not present mutations for 21-OH deficiency.

De novo mutations were found in two patients: mutation IVS2-13A/C > G, of maternal origin, and mutation 1760_1761insT, which could not be traced to any of the parents. In both cases parenthood was confirmed by multiple polymorphic markers, thus excluding the possibility of uniparental disomy.

Sequence changes that might represent novel substitutions were also found in this study: L226Q (1350T > A) in exon 6, A265V (1636C > T) and G274E (1663G > A) in exon 7. Mutation 1636C > T causes the substitution of alanine by valine, amino acids with similar properties, therefore being a neutral mutation that probably does not affect enzyme activity. On the other hand, the 1663G > A transition that results in substitution of the amino acid glycine by glutamic acid at position 274 (G274E), and the 1350T > A transversion that changes codon 226 from leucine to glutamine, are missense mutations which could cause a potentially pathogenic enzyme structural variation.

Discussion

Molecular analysis of the CYP21 gene was performed, to determine genetic aspects of 46 unrelated Brazilian patients with 21-OH deficiency. This is the first reported study on the distribution of mutations causing 21-OH deficiency in the Brazilian population of the Amazon region.

Direct sequencing of CYP21 exons allowed the identification of at least one mutation in 98% of the patients studied (46), corroborating previous findings that both large gene conversions and gene deletions are uncommon among Brazilian patients with 21-OH deficiency (Bachega et al., 2004).

The most frequent point mutation in our patient sample, IVS2-13A/C > G, is a severe mutation, categorized as group A, based on about 2% residual enzyme activity, established in vitro (Higashi et al., 1988). It is commonly associated to the SW form. This mutation is also the most common worldwide, except in some groups of patients of South Europe (Portugal, Italy and Spain), where it is less common and where mutation V281L has been identified as the most prevalent. Mutation V281L, which confers more than 20% enzymatic activity, is the most common variant associated to the nonclassical form of 21-OH deficiency in South European countries, reaching 34% in Spain (Ezquieta et al., 2002), 28% in Portugal (Friaes et al., 2006) and 24% in Italy (Balsamo et al., 2000). In North Europe, the most frequent mutation in NC alleles is P30L (Table 2). This mutation is also common in Argentine patients (25%) (Dain et al., 2002).

Mutation Q318X, the second most common mutation in our patient sample along with mutation V281L (frequency of 12%), is a severe mutation (null group) that abolishes the activity of the 21-OH enzyme. It has been found at relatively low frequencies (3% to 10%) in most of the studied populations, except in a sample of Japanese patients in which its frequency was 20% (Tajima et al., 1993). In our sample, the observed frequency of mutation Q318X was somewhat higher than those found in patients from Southeastern Brazil (6% and 7%) by Paulino et al. (1999) and Bachega et al. (2004), respectively.

Three other relatively common mutations found in our patients (1760_1761insT, Cluster E6, and P30L) also exhibited somewhat higher frequencies than those reported for patients from Southeast Brazil and for most of the populations studied worldwide (Table 2). Mutations 1760_1761insT and Cluster E6 are classified as null mutations, while P30L is considered a mild mutation (group C).

In our patient sample, the nine most common mutations found worldwide (Table 2) represented 80% of the total of mutations, 30% corresponding to null mutations (Q318X, 1760_1761insT, and Cluster E6); 34% to group A, with some residual enzyme activity (IVS2-13A/C > G); 2% to group B, with less than 10% residual enzyme activity (I172N); and 19% to group C mutations, with 10%-20% residual activity (V281L and P30L).

It is important to point out that the prevalence of null mutations in our sample is one of the highest ever reported (30%), higher than the frequencies reported for Brazilian patients from the Southeast region (23% by Bachega et al., 2004) and also for patients from Southern Europe (Portugal, Italy and Spain). These differences were due mainly to the high frequencies of the Q318X and 1760_1761insT mutations found in these patients from the Amazon region. On the other hand, our data are comparable to those found in Argentine patients (Dain et al., 2002). When the null and A group (IVS2-13A/C > G, predominantly) mutations are grouped together, the prevalence of mutations commonly associated to the SW and SV forms corresponds to 64% of the total in our patient sample, a value that is higher than those found in most of the previously studied populations, except in Japanese (64%-67%) and Mexican (62%) patients. In contrast, the frequencies found for group C mutations, both in our sample (19%) and in patients from South Brazil (20%), are lower than those reported for South European countries, particularly Spain (34%), Portugal (30%), and Italy (25%), as well as for Argentine, owing mainly to the high frequency of mutation V281L in the latter populations (Table 2).

The patient in which no mutations were found was clinically classified as presenting simple virilizing 21-hydroxylase deficiency, with ambiguous genitalia and undefined gender at birth. We suggest that this patient may carry mutations in regions which were not investigated, such as the promoter region, or in other genes involved in the cholesterol pathway, like 3β-hydroxysteroid dehydrogenase or 17α-hydroxylase, whose deficiency accounts for 5% of all cases of congenital adrenal hyperplasia (White and Speiser, 2000).

In conclusion, the most common mutations found worldwide were identified in patients from the Brazilian Amazon region, but the prevalence of null mutations was one of the highest in the world (30%), whereas the frequencies of group C mutation were lower than those reported for South European countries. However, overall, the mutations were found at frequencies that can be considered as the expected ones for a population resulting from the admixture of Europeans (predominantly Portuguese), African Blacks and Amerindians in proportions that differ from those estimated for South Brazilian populations, mainly regarding the contribution of Europeans, which is higher and more diversified in the Southeast, where the presence of Italian descendants besides the Portuguese is significant, mainly in the State of São Paulo. The available data also indicate a greater contribution of African Blacks in the Southeast, but a much lower Amerindian influence (Salzano, 2004).

Estimates of interethnic admixture for urban populations of the Amazon region based on blood group plus protein markers show average values of 47% European contribution, 12% African contribution, and 41% Amerindian contribution, with an increase of the Amerindian contribution from Belém towards Manaus and a decrease of the African contribution in the same direction. The average values found using nuclear DNA polymorphisms (STRs) were somewhat different from those obtained with the so-called classical polymorphisms, showing a larger European contribution (68% vs. 41%), similar values of African (14% vs. 12%), and a lower Amerindian contribution (18% vs. 41%). On the other hand, the two sets of results show values which are consistent with the Brazilian history, pointing to a higher Amerindian influence in the North (18%, 48%) and Midwest (11%, 17%) regions. Also according to history, the blood group + protein results suggest higher African contributions in the Northeast (26%) and Southeast (44%) regions (Salzano, 2004).

We suggest that interethnic mixture can explain the differences in the frequencies of some mutations between patients of the Brazilian Amazon and the Southeast regions. However, the differences found may also be due to the number of patients with the different clinical forms of 21-hydroxilase deficiency, which vary among the studies published so far.

Acknowledgments

We are grateful to the CAH patients for their collaboration and to the personnel of the Foundation Santa Casa de Misericórdia do Pará and University Hospitals Bettina Ferro de Souza and João de Barros Barreto, for assistance. This research was supported by grants from CNPq, CAPES, and Federal University of Pará.

Internet Resources

Received: September 17, 2007; Accepted: January 21, 2008.

Associate Editor: Francisco Mauro Salzano

• Bachega TA, Billerbeck AE, Madureira G, Marcondes JA, Longui CA, Leite MV, Arnhold IJand Mendonca BB (1998) Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab 83:4416-4419.
• Bachega TASS, Billerbeck AEC, Parente EB, Lemos-Marini SHV, Baptista MTM, Mello MP, Guerra Jr G, Kuperman H, Setian N, Damiani D, et al. (2004) Estudo multicêntrico de pacientes brasileiros com deficiência da 21-hidroxilase: Correlação do genótipo com o fenótipo. Arq Bras Endocrinol Metab 48:697-704.
• Balsamo A, Cacciari E, Baldazzi L, Tartaglia L, Cássio A, Mantovani V, Piazzi S, Cicognani A, Pirazzoli P, Mainetti B, et al. (2000) CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrin 53:117-125.
• Carrera P, Bordone L, Azzani T, Brunelli V, Garancini MP, Chiumello G and Ferrari M (1996) Point mutations in Italian patients with classic, non-classic, and cryptic forms of steroid 21-hydroxylase deficiency. Hum Genet 98:662-665.
• Dain LB, Buzzalino ND, Oneto A, Belli S, Stivel M, Pasqualini T, Minutolo C, Charreau EH and Alba LG (2002) Classical and nonclassical 21-hydroxylase deficiency: A molecular study of Argentine patients. Clin Endocrinol 56:239-245.
• Ezquieta B, Cueva E, Oyarzbal M, Oliver A, Varela JM and Jariego C (2002) Gene conversion (655G splicing mutation) and the founder effect (Gln318Stop) contribute to the most frequent severe point mutations in congenital adrenal hyperplasia (21-hydroxylase deficiency) in the Spanish population. Clin Genet 62:181-188.
• Ezquieta B, Oliver A, Gracia R and Gancedo PG (1995) Analysis of steroid 21-hydroxylase gene mutation in the Spanish population. Hum Genet 96:198-204.
• Ferenczi A, Garami M, Kiss E, Pek M, Sasvari-Szekely M, Barta C, Staub M, Solyom J and Fekete G (1999) Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 84:2369-2372.
• Friaes A, Rego AT, Aragues JM, Moura LF, Mirante A, Mascarenhas MR, Kay TT, Lopes LA, Rodrigues JC, Guerra S, et al. (2006) CYP21A2 mutations in Portuguese patients with congenital adrenal hyperplasia: Identification of two novel mutations and characterization of four different partial gene conversions. Mol Genet Metab 88:58-65.
• Grigorescu-Sido A, Schulze E, Grigorescu-Sido P, Heinrich U, Nistor T and Duncea I (2002) Mutational analysis and genotype-phenotype correlation in patients with classic 21-hydroxylase deficiency from Transylvania (north-west Romania). J Pediatr Endocrinol Metab 15:1505-1514.
• Higashi Y, Tanae A, Inoue H, Hiromasa T and Fujii-Kuriyama Y (1988) Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans: Possible gene conversion products. Proc Natl Acad Sci USA 85:7486-7490.
• Higashi Y, Yoshioka H, Yamane M, Gotoh O and Fujii-Kuriyama Y (1986) Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudogene and a genuine gene. Proc Natl Acad Sci USA 83:2841-2845.
• Jaaskelainen J, Levo A, Voutilainen R and Partanen J (1997) Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: Good correlation in a well defined population. J Clin Endocrinol Metab 82:3293-3297.
• Kapelari K, Ghanaati Z, Wollmann H, Ventz M, Ranke MB, Kofler R and Peters H (1999) A rapid screening for steroid 21-hydroxylase mutations in patients with congenital adrenal hyperplasia. Hum Mut 247:1-5.
• Koyama S, Toyoura T, Saisho S, Shimozawa K and Yata J (2002) Genetic analysis of Japanese patients with 21-hydroxylase deficiency: Identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21. J Clin Endocrinol Metab 87:2668-2673.
• Krone N, Braun A, Roscher AA, Knorr D and Schwarz HP (2000) Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85:1059-1065.
• Krone N, Roscher AA, Schwarz HP and Braun A (1998) Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. Clin Chem 44:2075-2082.
• Lee HH (2001) CYP21 mutations and congenital adrenal hyperplasia. Clin Gen 59:293-301.
• Lee HH, Lee YJ and Lin CY (2004) PCR-based detection of the CYP21 deletion and TNXA/TNXB hybrid in the RCCX module. Genomics 83:944-950.
• Morel Y and Miller WL (1991) Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. In: Harris H and Hirschhorn K (eds) Advances in Human Genetics. Plenum Press, New York, pp 1-68.
• New MI, White PC, Pang S, Dupont B and Speiser PW (1989) The adrenal hyperplasias. In: Scriver CR, Beaudet AL, Sly S and Valle D (eds) The Metabolic Basis of Inherited Disease. McGraw-Hill Press, New York, pp 1881-1918.
• Olney RC, Mougey EB, Wang J, Shulman DI and Sylvester JE (2002) Using real-time, quantitative PCR for rapid genotyping of the steroid 21-hydroxylase gene in a North Florida population. J Clin Endocrinol Metab 87:735-741.
• Ordoñez-Sánchez ML, Ramírez-Jiménez S, López-Gutierrez AU, Riba L, Gamboa-Cardiel S, Cerrillo-Hinojosa M, Altamirano-Bustamante N, Calzada-Léon R, Robles-Valdés C, Mendonza-Morfín F and Tusié-Luna MT (1998) Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: Identification of possible new mutations and high prevalence of apparent germline mutations. Hum Genet 102:170-177.
• Oriola J, Plensa I, Machuca I, Pavia C and Rivera-Fillat F (1997) Rapid screening method for detecting mutations in the 21-hydroxylase gene. Clin Chem 43:557-561.
• Paulino LC, Araujo M, Guerra GJ, Marini SH and De Mello MP (1999) Mutation distribution and CYP21/C4 locus variability in Brazilian families with the classical form of the 21-hydroxylase deficiency. Acta Paediatr 88:275-283.
• Salzano FM (2004) Interethnic variability and admixture in Latin America - Social implications. Rev Biol Trop 52:405-415.
• Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
• Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M and Tusié-Luna MT (1992) Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90:584-595.
• Tajima T, Fujieda K and Fujii-Kuriyama Y (1993) De novo mutation causes steroid 21-hydroxylase deficiency in one family of HLA-identical affected and unaffected siblings. J Clin Endocrinol Metab 77:86-89.
• Torres N, Mello MP, Germano CMR, Elias LLK, Moreira AC and Castro M (2003) Phenotype and genotype correlation of the microconversion from the CYP21A1P to the CYP21A2 gene in congenital adrenal hyperplasia. Braz J Med Biol Res 36:1311-1318.
• Trakakis E, Laggas D, Salamalekis E and Creatsas G (2005) 21-hydroxylase deficiency: From molecular genetics to clinical presentation. J Endocrinol Invest 28:187-192.
• Tusié-Luna MT and White PC (1995) Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. Proc Natl Acad Sci USA 92:10796-10800.
• White PC and Speiser PW (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21:245-291.
• White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B and Strominger JL (1985) Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci USA 82:1089-1093.
• White PC, New MI and Dupont B (1986) Structure of the human steroid 21-hydroxylase genes. Proc Natl Acad Sci USA 83:5111-5115.
• Wilson RC, Mercado AB, Cheng KC and New MI (1995) Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 80:2322-2329.
• Witchel SF, Smith R, Crivellaro CE, Della Manna T, Dichtchekenian V, Setian N and Damiani D (2000) CYP21 mutations in Brazilian patients with 21-hydroxylase deficiency. Hum Genet 106:414-419.
• Human Gene Mutation Database (HGMD), http://www.hgmd. cf.ac.uk/ac/gene.php?gene=CYP21A2

Publication Dates

• Publication in this collection
  18 Aug 2008
• Date of issue
  2008

History

• Received
  17 Sept 2007
• Accepted
  21 Jan 2008